Two participants with high-level therapeutically actionable variants (LOE1-2) identified through POG (prior clinical fluorescence in situ hybridization test was negative for BCR:ABL in lymphoma; no prior test was done for CCDC6:RET in papillary thyroid carcinoma) did not receive targeted therapy due to patient choice and no evidence of disease. This evidence concerns the gene CCDC6 and thyroid gland papillary carcinoma.